Published online Nov 25, 2022. doi: 10.5501/wjv.v11.i6.477
Peer-review started: April 20, 2022
First decision: May 31, 2022
Revised: June 12, 2022
Accepted: September 21, 2022
Article in press: September 21, 2022
Published online: November 25, 2022
Processing time: 216 Days and 21.1 Hours
The rapid increase in Coronavirus disease 2019 (COVID-19) patients has resulted in an increased number of patients with severe disease requiring prolonged ventilatory support and subsequently tracheostomy. Details regarding the timing, and safety of tracheostomy in the management of COVID-19 patients continue to evolve.
With the limited availability of literature regarding the outcomes of COVID-19 patients with tracheostomy, we attempted to study the clinical characteristics and multiple parameters affecting the outcomes in these patients.
Our research objective was to determine the all-cause mortality after tracheostomy and its relation with various risk factors in COVID-19 patients.
We conducted a retrospective observational study at a tertiary care hospital. The study included 73 adult COVID-19 patients admitted to the ICU between 1 April, 2020 and 30 September, 2021 who underwent tracheostomy as a result of acute respiratory failure due to COVID-19.
Seventy-three adult patients were included in the study with an average age of 52 ± 16.67 years, of which 52% were male. The average time for admission to tracheostomy was 18.12 ± 12.98 days while intubation to tracheostomy was 11.97 ± 9 days. The mortality rate was 71.2% and only 28.8% of patients were discharged alive. Greater age, severe COVID-19, mechanical ventilation, presence of shock and acute kidney injury were associated with a poor prognosis; however, early tracheostomy in intubated patients resulted in a better outcome.
The study showed that early tracheostomy (less than 10 days) was associated with reduced mortality with no added risk to the patient. Furthermore, the timing of tracheostomy should be decided on a case-by-case basis rather than following a strict rule.
A well designed randomised controlled trial should be performed to elucidate the potential benefit of early tracheostomy in COVID-19 patients.